approved-ken-speidel-2016 ncpa - complimenting and ... · complementing and enhancing your...
TRANSCRIPT
9/28/2016
1
Complementing and Enhancing Your Comprehensive Pharmacy Services with an Innovative Compounding Practicesponsored by Medisca, Inc.
© LP3 Network Inc. 2016. All rights reserved.
Facilitator
Kenneth R. Speidel
BS Pharm, PharmD, RPh, FIACP, FACA
Senior Surveyor, Pharmacy Compounding Accreditation Board
Senior Consultant, Gates HealthCare Associates
Professor of Pharmacy Practice, University of Findlay
Consultant, MEDISCA Network Inc.
Consultant/Facilitator, LP3 Network Inc.
9/28/2016
2
© LP3 Network Inc. 2016. All rights reserved.
Disclosure
Kenneth R. Speidel declare(s) no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.
Material presented during this CPE Activity reflects current literature on the subject and is presented without commercial bias, prejudice or influence.
Any personal opinions on the part of the presenter will be notably specified.
© LP3 Network Inc. 2016. All rights reserved.
Content Disclaimer
Due to the very nature of compoundingpharmacy practice, content may addresstherapeutic options that may or may not beapproved by Governmental regulatory bodies ormedical associations.
Participants of this Activity should verify allinformation and data before advocating anytherapies described in this educational activity.
9/28/2016
3
© LP3 Network Inc. 2016. All rights reserved.
The material presented is Copyright © 2016, LP3 Network Inc.
DISCLAIMER: The information contained in this program, which may include treatment modalities,diagnostic and therapeutic information, and instructions related to regulatory guidelines and currentstandards of practice for pharmacy compounding, is FOR EDUCATIONAL PURPOSES ONLY andshould not be taken as a treatment regimen, product indication, suggested treatment modality, orsuggested standard of practice. NOTE TO MEDICAL OR ALLIED HEALTH PROFESSIONAL: Anytreatments, therapies, or standards of practice must be fully investigated and prescribed by a dulylicensed medical practitioner in accordance with accepted professional standards and compendia. Anyregulatory or practice standard must be fully investigated by a licensed pharmacist in accordance withaccepted professional practice standards and compendia. The opinions and views expressed in thispresentation are those of the presenter only, and do not necessarily represent the views of LP3Network Inc.
Copyright and disclaimer
© LP3 Network Inc. 2016. All rights reserved.
Learning Objectives
• Provide an update on the current state of the compounding sector.
• Consider specific strategic organizational changes in response to the potential changes targeting compounding pharmacy.
• Identify areas within pharmacy operations that result in a duplication of resources and activities.
• Highlight opportunities to collaborate initiatives to reduce costs while improving services.
9/28/2016
4
© LP3 Network Inc. 2016. All rights reserved.
1 2 3
Compounding
• State of the Industry• Reasons for Compounding • What’s Driving the Growth
Intersections of TP & CP
• Parallel Universes• Business Image• Quality Assurance/QI• SOPs / Policies• Regulatory Compliance• Accreditation/Certification• Training /Competency• Academic Relationships• Marketing Activities• Patient Care Initiatives• Sales Initiatives
Synergistic Opportunities
• Clinical (MTM)• Collaborative Practices• Pain Management• Dermatological• Pediatrics• Geriatrics• HRT• Veterinary Services• Windows of
Opportunity
Outline
© LP3 Network Inc. 2016. All rights reserved.
9/28/2016
5
© LP3 Network Inc. 2016. All rights reserved.
February 23, 2015
CBS News aired a story about unethical marketing and billing of compounded pain creams.
The report exposed a telemarketing scheme:
• Get physicians to write prescriptions for patients who mentioned they were experiencing pain.
• The company would bill extremely high amounts of money to the patient’s insurance company and ship the medication.
• They often did not charge the co-pay to the patient.
Compounded Pain Creams Make Headlines For Unethical Marketing/Billing Scheme
© LP3 Network Inc. 2016. All rights reserved.
• ….Justice Department to make $40 million available for victims of deadly meningitis outbreak…Post Nation
• June 2016 …HHS OIG Data Brief • Part D Spending onOpioids and Substantial Growth in Compounded DrugsRaise Concerns
• July 7, 2016…High Importance! FDA issued two draft guidance documents describing how the FDA would implement provisions of federal law that restrict compounding human drug products that are essentially copies of commercially available or approved drug products.
9/28/2016
6
© LP3 Network Inc. 2016. All rights reserved.
July 20, 2016
• Citing Unnecessary Risks, FDA Proposes New Restrictions on Certain Compounded Drugs
Jul 25, 2016
• To avoid shortages, FDA allows imports from 8 drug plants banned for quality shortfalls
August 29, 2016
• China Drug Sales to the U.S. Grow Despite Safety Concerns at Home Chinese drugs and pharmaceutical ingredients jumped 3 percent to $56 billion last year. Yet even as China’s drug industry has grown in global stature, so have questions about the safety of its products
Aug 31, 2016 • FDA finds China manufacturing plant full of holes, chipped paint,
and insects.
© LP3 Network Inc. 2016. All rights reserved.
• Regulators• Boards of Pharmacy• DEA • OSHA• FDA
Who Regulates Compounding Pharmacies?
9/28/2016
7
© LP3 Network Inc. 2016. All rights reserved.
Reactive
• Meningitis
• Ocular Injections
• Institutionally based
• Veterinary
Proactive
• Requires Quality Management/Assurance
• Premeditated standard compliance
• Standards are in place for a reason
Why has the role of the USP increased in compounding regulations?
© LP3 Network Inc. 2016. All rights reserved.
• <795> Pharmaceutical Compounding – Non-sterile Preparations
• <797> Pharmaceutical Compounding – Sterile Preparations
• <1160> Pharmaceutical Calculations in Prescription Compounding
• <1163> Quality Assurance in Pharmaceutical Compounding
• <1176> Prescription Balances and Volumetric Apparatus
• <800> Hazardous Drugs – Handling in The Healthcare Setting
Application of the following:
• <51> Antimicrobial Effectiveness Testing
• <71> Sterility Tests
• <85> Bacterial Endotoxins Test
• Others
USP Standards
9/28/2016
8
© LP3 Network Inc. 2016. All rights reserved.
• The demand for customized prescription medication is on the rise as drug manufacturers do not always meet the distinct requirements of each patient
• Specialty/compounding pharmacy significant growth• Compounding pharmacy a core competency • Improved/unique way to set a pharmacy apart• Identifies pharmacy as a part of the leading edge• Effective/unique patient follow-up (compliance et al.)• New markets continuing to open up
Where there is Change Opportunities
© LP3 Network Inc. 2016. All rights reserved.
Opportunity Pharmaceutical Compounding
9/28/2016
9
© LP3 Network Inc. 2016. All rights reserved.
History Tells Us…
That The CUSTOM in Compounding Has Always Been
The CUSTOMization of Drug Therapy
Compounding pharmacists work directly with prescribers including physicians, nurse practitioners and veterinarians to create customized medication solutions for patients and animals whose healthcare needs cannot be met by manufactured medications.
http://www.iacprx.org/default.asp - accessed 12/01/2014
© LP3 Network Inc. 2016. All rights reserved.
Practitioners…
• Using Manufactured Products, are trying to match a patient to a product.
• Using Compounded Preparations, match a compounded formulation to a patient.
One Dose, One Delivery System DOES NOT FIT ALL
The compounding pharmacist that will differentiate themselves from others will believe in the ideology of matching a compounded preparation to the patient.
9/28/2016
10
© LP3 Network Inc. 2016. All rights reserved.
Compounding pharmacists must have proven competence in:
Pharmaceutical Compounding: Individualized Patient Care
• pharmaceutics
• pharmacology
• pharmacogenomics
• formulations
• pharmaceutical chemistry
• medicinal chemistry
• physiology and pathophysiology
• microbiology
• non-sterile compounding & sterile compounding
The Role of the Compounding Pharmacist is the…
Individualization of Pharmacotherapy to Optimize Outcomes
© LP3 Network Inc. 2016. All rights reserved.
Pharmacotherapeutic Customization
• Physiological Differences:– Skin– Mucus Membranes– Allergenicity
• Systemic Effects - Need for targeted treatment approach• Complex Symptom Presentation• Social/Environmental/Occupational Differences• Clinical Pharmaceutics• Pharmacodynamic Differences:
– Drug Class – Within the Same Class
• Pharmacogenomics
9/28/2016
11
© LP3 Network Inc. 2016. All rights reserved.
Individualize Based on a Patient’s Genomic Composition: Pharmacogenomics
• Based on the individual’s human genome.
• Better selection of drugs:–Coffee anyone? Sorry, does it keep you up at
night?• CYP1A2
• Better selection of dose.
• Better selection of excipients.
• Compounding plays a major role!
© LP3 Network Inc. 2016. All rights reserved.
• Clinical Pharmacy Practice
• Problem Solving Centers
• Difficult Cases are referred
• Off-label use potentials
• Broadened ability to provide pharm/care excellence
Compounding Pharmacy = A Patient-Centric Practice
9/28/2016
12
© LP3 Network Inc. 2016. All rights reserved.
US Market:• 2003: approx 1% of all prescriptions are compounded = 30
million prescriptions = $1.5 billion- 2.3 % of dispensed prescriptions for independent
community pharmacies in Illinois, Missouri, Kansas, and Iowa
• 2016: approx 2-3% of all prescriptions are compounded = 110 million prescriptions = $5.5 billion
A look at the United Kingdom: • 2015: £ 74 million ($USD 99.4 million)
McPherson TB, Fontane PE, Jackson KD, Martin KS, Berry T, Chereson R, Bilger R. Prevalence of compounding in independent community pharmacy practice. J Am Pharm Assoc (2003) 2006 Sep‐Oct; 46(5):568‐573.Statement of Steven K. Galson, M.D., M.P.H., Acting Director, Center for Drug Evaluation and Research. U.S. Food and Drug Administration, Department of Health and Human Services, before the Senate Committee on Health, Education. Labor, and Pensions hearing on "Federal And State Role In Pharmacy Compounding And Reconstitution: Exploring The Right To Mix To Protect Patients." October 23, 2003. Food and Drug Administration. http://www.fda.gov/ola/2003/pharmacycompound1023.html.
Compounding Market Overview
© LP3 Network Inc. 2016. All rights reserved.
• Increase in frequency of drug shortages in the US
• Currently, approximately 300 drugs in shortage
http://www.gao.gov/products/GAO‐14‐194
Manufacturer Drug Shortages
9/28/2016
13
© LP3 Network Inc. 2016. All rights reserved.
• Increase in drug shortages• Increase in physician visits• Aging population• Growth and understanding of
Pharmacogenomics• Increase in number of prescriptions dispensed• Increase in the number of pets• Increased awareness of pharmaceutical
options among consumers • Rising demand for personalized medicine
Compounding Pharmacy Growth Drivers
© LP3 Network Inc. 2016. All rights reserved.
1 2 3
Compounding
• State of the Industry• Reasons for Compounding • What’s Driving the Growth
Intersections of TP & CP
• Parallel Universes• Business Image• Quality Assurance/QI• SOPs / Policies• Regulatory Compliance• Accreditation/Certification• Training /Competency• Academic Relationships• Marketing Activities• Patient Care Initiatives• Sales Initiatives
Synergistic Opportunities
• Clinical (MTM)• Collaborative Practices• Pain Management• Dermatological• Pediatrics• Geriatrics• HRT• Veterinary Services• Windows of
Opportunity
Outline
9/28/2016
14
© LP3 Network Inc. 2016. All rights reserved.
Traditional Pharmacy Compounding Pharmacy
Universes
It’s Time We Intersect These Parallel Universes
Parallel Universes
© LP3 Network Inc. 2016. All rights reserved.
Traditional Pharmacy Universe
• Pharmaceutical Care• BOP, DEA• Accreditation Requirements• Training Needs• University Affiliations• Patients with Pain• Pts. with Hormone Imbalances• Pediatric Patients• Geriatric Patients• Veterinary Prescriptions• Pts. with Dermatological Needs• Marketing Initiatives• Prescriber Relations
Compounding Pharmacy Universe
• Clinical Consultations• Regulatory Compliancy FDA• Accreditation Requirements• Quality Assurance Plans• Advanced training required• University Affiliations• Patients with Pain• Pts. with Hormone Imbalances• Pediatric Patients• Geriatric Patients• Veterinary Prescriptions• Pts. with Dermatological Needs• Marketing Initiatives• Prescriber relations
Looking at The Universes Through Your Telescope
9/28/2016
15
© LP3 Network Inc. 2016. All rights reserved.
Intersections Traditional Community Pharmacy & Compounding Pharmacy Practices
• Market Image• QI/QA• Standard Operating Procedures• Regulatory Compliance• Certification / Accreditation• Training / Competency• Academia• Marketing• Patient Care• Sales
© LP3 Network Inc. 2016. All rights reserved.
• Clinical Practice
• Problem Solver
• Educator
• Healthcare Provider
• Evidence-Based Practice
• Chemist
• Individualized Pharmacotherapeutics
Your Market Image Enhanced
9/28/2016
16
© LP3 Network Inc. 2016. All rights reserved.
© LP3 Network Inc. 2016. All rights reserved.
• Regulatory Requirement in many States. Accreditation Requirements.
• Assign a designated organizational QA associate
• Conduct joint projects (indicators)
• Trending Quality Related Events (QREs)
• Shipping/mailing temperature integrity tests
• Mock recall drills
• Hazardous chemical/drug training (USP/OSHA)
• Telephone waiting time
• Prescription pick-up rate
Intersecting Quality Assurance / Improvement Activities
9/28/2016
17
© LP3 Network Inc. 2016. All rights reserved.
• Regulatory / Accreditation Requirement
• Many Community Pharmacies are naive to SOPs
• Reduces variability by conforming processes
• Critical SOP Intersections• Grievance/Complaints
• Training and Competency
• Recall
• Cleaning / Sanitizing
• Controlled Substance Management
Intersecting Standard Operating Procedures
© LP3 Network Inc. 2016. All rights reserved.
• DEA Compliance Assessment
• OSHA and USP <800> safety assessments
• Board of Pharmacy Rules Gap Analysis
• EPA - Chemical Waste Disposal Management
• Local Municipalities
Intersecting Regulatory Activities
9/28/2016
18
© LP3 Network Inc. 2016. All rights reserved.
The Increasing Importance of Pharmacy Accreditation
As competition grows among pharmacy service providers one thing has become evident:• pharmacy accreditation is no longer an option, it is now an obligation.
Not participating in accreditation may:• Decrease your competitive edge and compelling points of differentiation• Your Pharmacy may lose the ability to work with some major payers and
government entities who now require accreditation as a term of doing business
IntersectingAccreditation / Certification Activities
© LP3 Network Inc. 2016. All rights reserved.
Select Pharmacy Accreditation/Certification Services
• ACHC (Accreditation Commission for Health Care)• PCAB (Pharmacy Compounding Accreditation Board)
• VPP (Verified Pharmacy Program)• CPPA (Center for Pharmacy Practice Accreditation) • URAC (Specialty Pharmacy Focus) • HQAA (Healthcare Quality Association on
Accreditation)• Joint Commission (Hospitals and other settings)• CHAP (Community Health Accreditation Partner)
Accreditation / Certification
9/28/2016
19
© LP3 Network Inc. 2016. All rights reserved.
• Disease State Management
• Hazardous Drug Management
• Veterinary Pharmacy
• Hormone Therapies
• Pain Management
• Pediatrics
• Basic Compounding Competencies
Intersecting Training Competency Initiatives
© LP3 Network Inc. 2016. All rights reserved.
• Market Image
• Several Clinical Settings to Offer
• Research Opportunities / Database Access
• IPPI (Introductory Pharmacy Practice Experience)
• APPI (Advanced Pharmacy Practice Experience)
• Research Opportunities
Intersecting Associations with Academia
9/28/2016
20
© LP3 Network Inc. 2016. All rights reserved.
• Captive patient and prescriber audience • FTE and Mkt expense savings
(Economies of Scale) • Larger offering• Diverse Prescriber Field• “One Stop Shop”• Fax blasts, bag stuffers, on-site
opportunities.• Co-Travelers
Intersecting Marketing Initiatives
© LP3 Network Inc. 2016. All rights reserved.
• MTM (Medication Therapy Management)
• Familiarity and Convenience
• Collaborative Practice Agreements
• Compliance
• Counseling
Intersecting Patient Care Activities
9/28/2016
21
© LP3 Network Inc. 2016. All rights reserved.
Compounding Pharmacy + Community Pharmacy A Patient-Centric Approach
The Advantages of providing your patients with individualized/tailored medications
© LP3 Network Inc. 2016. All rights reserved.
• Complimentary Sales • Services
• Nutritionist• Herbalist• Health Coach• Naturopathic practitioner
• Products• Supplements (Quality Proven)
• HRT selenium, melatonin, adrenal support, thyroid support, metabolic support
• Pain Management magnesium glycinate, alpha-lipoic acid• Pediatrics liquid supplements, specialty AA’s,
additive/preservative free, dosing devices • Payer Contracts• Health System Preferred Provider Agreements
Intersecting Sales Initiatives
9/28/2016
22
© LP3 Network Inc. 2016. All rights reserved.
1 2 3
Compounding
• State of the Industry• Reasons for Compounding • What’s Driving the Growth
Intersections of TP & CP
• Parallel Universes• Business Image• Quality Assurance/QI• SOPs / Policies• Regulatory Compliance• Accreditation/Certification• Training /Competency• Academic Relationships• Marketing Activities• Patient Care Initiatives• Sales Initiatives
Synergistic Opportunities
• Clinical (MTM)• Collaborative Practices• Pain Management• Dermatological• Pediatrics• Geriatrics• HRT• Veterinary Services• Windows of
Opportunity
Outline
© LP3 Network Inc. 2016. All rights reserved.
• Medication Therapy Management (MTM)• Endocrine Imbalances• Pain Management
• Collaborative Practice Agreements (CPA’s)• Niche Market Intersection
• Pediatrics• Geriatrics• Hormone therapy• Pain management therapy• Veterinary
Synergistic Opportunities
9/28/2016
23
© LP3 Network Inc. 2016. All rights reserved.
Medication therapy management (MTM) is medical care provided by pharmacists whose aim is to optimize drug therapy and improve therapeutic outcomes for patients.
MTM 5 core components: • a medication therapy review (MTR), • a personal medication record (PMR), • medication-related action plan (MAP), • pharmacist intervention and/or referral, • documentation and follow
Medication Therapy Management (MTM)
© LP3 Network Inc. 2016. All rights reserved.
Diabetes is a predominant diagnosis responsive to MTM• Multiple endocrinopathies
• Thyroid• Adrenal• Gonadal
• Pain Management• Diabetic neuropathy is the most common complication of
diabetes mellitus (DM), affecting as many as 50% of patients with type 1 and type 2 DM
• Nutritional Deficiencies • Supplements• Lifestyle• Health Coach
MTM (continued)
9/28/2016
24
© LP3 Network Inc. 2016. All rights reserved.
Diabetes is a predominant diagnosis responsive to MTM• Intersection Opportunities
• Hormone Consultation and Therapies (adrenal, thyroid, gonadal)• Pain Consultation and Therapies (topical, dorsal horn, systemic)
• Intersecting pathophysiology with pharmacology using a multi-modal tx• Decrease systemic side effects• Decrease opioid use• Maintaining income
• Increasing peripheral circulation• Supplements (Must Prove Quality)
• Alpha-lipoic acid• Magnesium glycinate• Vanadium• Vitamin D3
• Chromium
MTM + Clinical Consultations + Compounds + Supplements = $ Revenue
MTM (continued)
© LP3 Network Inc. 2016. All rights reserved.
Treat the Pain, Know The Pathophysiology
DIABETIC PERIPHERAL NEUROPATHY: PATHOPHYSIOLOGICAL PATHWAYS KNOWN OR HYPOTHESIZED
1
Degenerative small nerve fiber neuropathy leads to: formation of neuromas on differentiated axon, hyper-excitability of peripheral nerve terminals, loss of sensation and dysfunctional signaling perceived as uncontrollable itching.
2
Insulin deficiency results in less insulin-like growth factor (IGF) which protects mitochondrial function during hyperglycemia, and damages neuronal cells.
3 Constant signaling leads to central excitation through normal channels.
4Hyperglycemia in spinal column, through increased flux in aldose reductase and induction of COX-2 and prostaglandin release, leads to central inflammation.
5Cross talk connections between neurons overwhelms the descending noxious inhibitory control system.
6 Decrease in some of the descending inhibitory pathways.
9/28/2016
25
© LP3 Network Inc. 2016. All rights reserved.
Know The Physiological Targets: Points of Interception
- - - - - - - - - - -- - - - - - - - - - -
- - - - - - - - - - -- - - - - - - - - - -
Stop action potentialBlock ion channel
Block action potential
Alter release of neurotransmitters
Facilitate or enhance
neurotransmitter reuptake
Act on receptor sites causing
same transmitter effect: Agonism
Block receptor site: Antagonism
Decrease activity of enzymes that destroy
neurotransmitters
© LP3 Network Inc. 2016. All rights reserved.
• Medication Therapy Management• Endocrine Imbalances
• Pain Management
• Collaborative Practice Agreements (CPAs)
• Niche Market Intersection• Pediatrics
• Geriatrics
• Hormone therapy
• Pain management therapy
• Veterinary
Synergistic Opportunities
9/28/2016
26
© LP3 Network Inc. 2016. All rights reserved.
Collaborative practice agreements (CPAs) prescribers (generally physicians) authorize pharmacists to engage in specified activities such as adjusting and/or initiating drug therapy, to help patients achieve more effective and efficient drug therapy outcomes.• Authority for a CPA is generally incorporated in the state
pharmacy practice act.• Some boards of pharmacy have promulgated regulations
creating CPAs based on broad authorizing language.
Collaborative Practice Agreements
© LP3 Network Inc. 2016. All rights reserved.
CPAs are commonly being used for:• immunizations, • emergency contraception, • asthma therapy management, • dyslipidemia therapy management, • warfarin anticoagulant therapy
management, • diabetic therapy management, • smoking cessation therapy, • flu/antiviral therapy.
Collaborative Practice Agreements
9/28/2016
27
© LP3 Network Inc. 2016. All rights reserved.
For pharmacists to participate effectively in CPAs, the following conditions should exist:
a collaborative practice agreement; o access to patients; o access to medical records; o a defined level of education, training, knowledge,
skills, and abilities; o documentation of clinical activities; o and payment for a pharmacist’s activities.
Collaborative Practice Agreements
© LP3 Network Inc. 2016. All rights reserved.
A clinical compounding practice can expand the opportunities to enhance and potentially expand CPA’s:
o Endocrine imbalances o Topical treatments for neuropathies o Dosage form adjustment in specific pt. populationso Modification of a delivery system in order to
improve outcomes and/or compliance.
Collaborative Practice Agreements
9/28/2016
28
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
CommunityRX
CompoundingRX
Universes Intersect
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Intersect
9/28/2016
29
© LP3 Network Inc. 2016. All rights reserved.
• At least 100 million adults have common chronic pain conditions (USA) & 18.9% of adults have chronic pain conditions (Canada)
• Healthcare providers wrote 259 million prescriptions for opioid pain medications (USA-2012)
• Over 420,000 emergency department visits were related to the misuse or abuse of narcotic pain relievers (USA-2011)
• Almost 2 million Americans abused or were dependent on prescription opioids (2014).
Institute of Medicine of the National Academies Report. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, 2011. The National Academies Press, Washington DC.http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm; http://www.cdc.gov/drugoverdose/data/overdose.htmlSchopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Research & Management : The Journal of the Canadian Pain Society. 2011;16(6):445‐450.
Pain Management – The Market
© LP3 Network Inc. 2016. All rights reserved.
• Every day, over 1,000 people are treated in emergency departments for misusing prescription opioids (USA-2013)
• From 1999 to 2014, more than 165,000 persons died from overdose related to opioid pain medication (USA)
• Over the last decade, there has been an increase in opioid (narcotic) pain medication-related deaths in Canada and the USA.
Institute of Medicine of the National Academies Report. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, 2011. The National Academies Press, Washington DC.http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm; http://www.cdc.gov/drugoverdose/data/overdose.htmlSchopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Research & Management : The Journal of the Canadian Pain Society. 2011;16(6):445‐450.
Pain Management – The Market
9/28/2016
30
© LP3 Network Inc. 2016. All rights reserved.
• Direct application to affected site
• Reduction in systemic effects
• Reduction in drug concentration in the blood
• Reduction in first pass metabolism
• Painless administration
Compounding for Pain Management -Advantages
© LP3 Network Inc. 2016. All rights reserved.
• Ability to combine multiple drugs in one preparation
• Ability to choose desired base
• Increase patient compliance / convenience
• Ability to continually customize and modify based on a patient’s changing needs
• Avoidance of opioid and narcotic dependency
Compounding for Pain Management -Advantages
9/28/2016
31
© LP3 Network Inc. 2016. All rights reserved.
• Improved Outcomes
• Decreased Side Effects
• Decreased Drug Interactions
• Decreased Opioid Use
• Decreased Medication Costs
• Multimodal Approach to Pain Treatment in 1 formulation
• Prescriber Loyalty
• Supplement Sales
• Payor Access
• Revenue $
Potential Intersection Opportunities Pain Management
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Intersect
9/28/2016
32
© LP3 Network Inc. 2016. All rights reserved.
Most popular dermatological conditions benefiting from compounded preparations:
• Acne• Hair loss• Pruritus such as eczema and psoriasis• Calluses and warts• Corrective cosmetic• Topical fungus and rashes• Anti-aging
Dermatology
© LP3 Network Inc. 2016. All rights reserved.
Cosmetics (Dermaceuticals)
• Many patients have multiple skin concerns and have difficulty finding a traditional, mass-market skin care product that meets their needs
• Customized to the patient’s needs by carefully selecting the right moisturizing agents, non-irritating bases and hypoallergenic products to treat your concerns based on your skin type
• Deliver active cosmetic boosters and a unique texture perfectly adapted to your skin’s needs
• Personalized and multi-functional solution
9/28/2016
33
© LP3 Network Inc. 2016. All rights reserved.
• Individualized Dermatological Pharmacotherapy• Decreased Side Effects• Non-irritating bases and delivery system• Unique treatments without commercial product
• Topical B12
• Topical Estriol• Topical Hydroquinone
• Tailored Dermaceuticals (Cosmetics)• Private Label - your own line
• Prescriber Loyalty• Supplement Sales• Payor Access• Revenue $
Potential Intersection Opportunities Dermatology
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Intersect
9/28/2016
34
© LP3 Network Inc. 2016. All rights reserved.
• Many Community Pharmacies are not comfortable compounding for kids – a simple suspension is sometimes not so simple
• Compounders are Formulation Experts • Reduce the risk of adverse drug events relating to
accidental overdoses for APIs with narrow therapeutic index
• Small amounts are desired or the dose required is not easily manipulated from the commercially available strength/dosage
Pediatrics
© LP3 Network Inc. 2016. All rights reserved.
• Increase in compliance by masking the taste through the use of flavors.
• Compounders can give the child the option of choosing their flavor or even combining multiple flavors if desired
Pediatrics
9/28/2016
35
© LP3 Network Inc. 2016. All rights reserved.
• Special populations, such as children with behavioral problems, diabetes, sensitivities or allergies in which symptoms can range from minor irritations to potentially causing anaphylactic shock.
• Additional Special Populations within:• Autism• Eosinophilic esophagitis• Resistant diaper rash
Pediatrics
© LP3 Network Inc. 2016. All rights reserved.
• Compounders can make chewable tablets or liquids for patients that have difficulty swallowing a large tablet or capsule
• Child-friendly dosage forms include gummies, troches, lozenges, lollipops, oral liquid, suppositories
Pediatrics
9/28/2016
36
© LP3 Network Inc. 2016. All rights reserved.
• Specializing in formulation expertise. Most community pharmacies are not equipped to formulate for children.• Lack of precise equipment (i.e., analytical balance, particle size
reduction/conformation)
• Flavoring experts• Unique treatments without the availability of commercial
products.• Prescriber Loyalty• Supplement Sales, dye free, preservative free, amino acid
supplements• Opens market to Pediatric Sports Medicine • Payor Access• Revenue $
Potential Intersection Opportunities Pediatrics
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Intersect
9/28/2016
37
© LP3 Network Inc. 2016. All rights reserved.
• Growing number of senior citizens
• Represent 30% of the annually prescribed medications
Salom IL, Davis K. Prescribing for older patients: How to avoid toxic drug reactions. Geriatrics 1995;50:37‐44.
Geriatrics – The Market
© LP3 Network Inc. 2016. All rights reserved.
• The concerns we have with pediatric patients are often shared with the elderly
• Difficulty swallowing tablets and capsules because of conditions such as dry mouth*
• The need to take numerous medications• Lower doses required• Easier administration• Combination of multiple drugs into one
preparation
Geriatrics - Advantages
9/28/2016
38
© LP3 Network Inc. 2016. All rights reserved.
Common dosage forms :
• Oral liquids• Topical and/or transdermal creams• Ointments• Gels• Rapid Dissolving Tablets (RDT)• Sublingual sprays• Troches• Lozenges• Injections• Suppositories
Geriatrics
© LP3 Network Inc. 2016. All rights reserved.
• Potentially reduce systemic side effects by using topical options • NSAIDs
• Topical Shingles Treatments
• Anal Fissures
• Unique treatments without the availability of commercial products
• Seminars and Events (Brown Bag, Used Rx Destruction)
• Supplement Sales specific to the seniors
• Assisted Living
• Revenue $
Potential Intersection Opportunities Geriatrics
9/28/2016
39
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Intersect
© LP3 Network Inc. 2016. All rights reserved.
Pinkerton JV, Constantine GD. Menopausal Hormone Therapy (MHT) Usage: FDA‐Approved MHT Has Decreased While Compounded Non‐FDA Approved MHT Has Increased. Poster Board FRI‐124 Hyperandrogenic Disorders and Menopause. Presented at: The Endocrine Society Annual Meeting; March 5‐8,2015, San Diego.
Annual Number of Prescriptions
Market Value ($USD)
Commercial MHT market 36 million $3 billion – $4 billion
Custom compounded MHT market 26 – 36 million $1 billion – $2 billion
Most compounding pharmacists project a 5% to 25% growth in the compounding business over the next 2 years.
Hormone Replacement Therapy –The Market
9/28/2016
40
© LP3 Network Inc. 2016. All rights reserved.
• Treatment has become more complex and all-encompassing
• HRT doesn’t only apply to women- Andropause
• Compounded Options afford prescribers and patients options.
• Core Health Consumers prefer compounded HRT.
Hormone Replacement Therapy
© LP3 Network Inc. 2016. All rights reserved.
• Can provide the lowest effective dose without having to worry about the fixed dosing increments set by commercial products
• Provides hormones not commercially available.• Provide dosage forms of hormones not commercially
available, which delivers reported beneficial effects. • Provide unique and not commercially available delivery
systems in order to enhance clinical effects and decrease potential unwanted effects (RDTs, Troches, Pessaries, Topical, etc.)
• Minimize multiple medications being administered - multiple hormones can be combined into one preparation
• Increase patience compliance resulting in successful HRT
Hormone Replacement Therapy
9/28/2016
41
© LP3 Network Inc. 2016. All rights reserved.
• Affords Physicians and Patients Options
• Individualization of Pharmacotherapy
• Clinical HRT Consults
• Unique treatments without commercial products• Estriol
• Intravaginal DHEA
• Transmucosal Delivery Systems
• Prescriber Loyalty
• Supplement Sales
• Payor Access
• Revenue $
Potential Intersection Opportunities HRT
© LP3 Network Inc. 2016. All rights reserved.
• Pain management
• Dermatology
• Pediatrics
• Geriatrics
• Hormone replacement therapy
• Veterinary
Universes Inersect
9/28/2016
42
© LP3 Network Inc. 2016. All rights reserved.
• Estimated 96 million Cats in US
• Estimated 80 million Dogs in the US
• Over 105 000 practicing veterinarians in USA
• Expected growth in number of pets
• By effectively handling a household pet prescription, you can obtain the pet owner’s business too
• Most Community Pharmacies Losing Market
• Community Pharmacists not Trained in Veterinary Pharmacy
www.avma.org/KB/Resources/Reports/Documents/Veterinarian‐Workforce‐Final‐Report.pdfwww.avma.org/KB/Resources/Statistics/Pages/Market‐research‐statistics‐US‐veterinarians.aspxwww.canadianveterinarians.net/documents/canada‐s‐pet‐wellness‐report2011www. ibisworld.com
Veterinary – The Market
© LP3 Network Inc. 2016. All rights reserved.
Veterinary - Opportunities
• Domestic animals
• Food animals
• Exotic species
• Minor species
9/28/2016
43
© LP3 Network Inc. 2016. All rights reserved.
• Fewer numbers of drugs available to veterinarians
• Species-specific requirements• Personnel safety when administering
medication to animals that is difficult to handle.• Transdermal Options, Paw Paste, Reverse
Gels, Ear Mites.
Veterinary - Advantages
© LP3 Network Inc. 2016. All rights reserved.
Common dosage forms :• Oral pastes• Paw Paste• Chewable treats• Oral liquids• Topical Reverse Gels• Capsules• Injections• Topical or transdermal preparations• Powders (to be mixed with food)
Veterinary
9/28/2016
44
© LP3 Network Inc. 2016. All rights reserved.
• Marketing Potential treating the whole family• Unique treatments without commercial product
• Paw Paste• Transdermal to pinna of ear• Reverse Gels
• Improving Vet Office Efficiencies• Improving Compounding Practices vs Vet Office• Animal Health Products Supplement Sales• Relationship with Law Enforcement• Revenue $
Potential Intersection OpportunitiesVet Pharmacy
© LP3 Network Inc. 2016. All rights reserved.
1 2 3
Compounding
• State of the Industry• Reasons for Compounding • What’s Driving the Growth
Intersections of TP & CP
• Parallel Universes• Business Image• Quality Assurance/QI• SOPs / Policies• Regulatory Compliance• Accreditation/Certification• Training /Competency• Academic Relationships• Marketing Activities• Patient Care Initiatives• Sales Initiatives
Synergistic Opportunities
• Clinical (MTM)• Collaborative Practices• Pain Management• Dermatological• Pediatrics• Geriatrics• HRT• Veterinary Services• Windows of
Opportunity
Outline
9/28/2016
45
© LP3 Network Inc. 2016. All rights reserved.
• Consider this: avg pharmacy with 100 patients/day
• 5% (5 patients) requiring a compounded med
• The Average retail of compounded med = $901
• Annually = $117,450 addition to gross profit
• Compounding increases revenue, while offering options to your MD and patient base with targeted/personalized pharmaceutical care choices
1 http://lab.express‐scripts.com/lab/insights/drug‐options/closing‐the‐compounding‐loophole
Making Cents (₵) of it all …
© LP3 Network Inc. 2016. All rights reserved.
Windows of Opportunity
Seeing through
the biggest windows
of them all.
9/28/2016
46
© LP3 Network Inc. 2016. All rights reserved.
Windows of Opportunity
Patient Care
Business Development
Marketing
Regulatory / AccreditationParameters
PracticalImplementation
© LP3 Network Inc. 2016. All rights reserved.
Make These Windows Become One
Quality Assurance – AccreditationRegulatory Compliancy – Certification
Marketing – Business ImageTraining – Competency – Academia
Clinical – Pt. Care – MTM – Collaborative PAsComplimentary Sales – Supplements – Services
“ What Obstructs Your View? Enlarge YOUR Window. See The 360° Panorama! Keep Your
Windows Clean”
9/28/2016
47
© LP3 Network Inc. 2016. All rights reserved.
How Clean Are These Windows?
© LP3 Network Inc. 2016. All rights reserved.
Questions???
What Opportunities Exist In Your Universe??
What Questions About The Universe Do You Have Today???
9/28/2016
48